TCT-312 The Impact of Platelet-Fibrin Clot Strength and Endogenous Fibrinolytic Activity on Adverse Cardiac Events After Percutaneous Coronary Intervention in Patients with Coronary Artery Disease

TCT-312 The Impact of Platelet-Fibrin Clot Strength and Endogenous Fibrinolytic Activity on Adverse Cardiac Events After Percutaneous Coronary Intervention in Patients with Coronary Artery Disease

TEG® system indicates “Platelet-Fibrin Clot Strength” (MAthrombin: maximal amplitude of the clot dynamics) and endogenous fibrinolytic activity (LY30: percentage of the clot lysis at 30 min) together. Conclusion This study is the first to show the clinical impact of clot strength and endogenous fibr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2017-10, Vol.70 (18), p.B128-B129
Hauptverfasser: Ahn, Jong-Hwa, Jeong, Young-Hoon
Format: Artikel
Sprache:eng
Schlagworte:
Angioplasty
Blood platelets
Cardiology
Cardiovascular disease
Coronary artery
Coronary artery disease
Fibrin
Health risk assessment
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:TEG® system indicates “Platelet-Fibrin Clot Strength” (MAthrombin: maximal amplitude of the clot dynamics) and endogenous fibrinolytic activity (LY30: percentage of the clot lysis at 30 min) together. Conclusion This study is the first to show the clinical impact of clot strength and endogenous fibrinolytic activity on MACE after PCI in CAD patients, which may indicate that coagulation profiles can be important risk factors for atherothrombotic events in these patients.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2017.09.396